{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T22:19:19Z","timestamp":1784585959451,"version":"3.55.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1016\/j.bcmd.2005.12.021","type":"journal-article","created":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T15:16:15Z","timestamp":1141226175000},"page":"199-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Platelet-mediated thrombotic complications in patients with ET: Reversal by aspirin, platelet reduction, and not by coumadin"],"prefix":"10.1016","volume":"36","author":[{"given":"Jan Jacques","family":"Michiels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zwi","family":"Berneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Schroyens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Koudstaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lindemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huub H.D.M.","family":"van Vliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2005.12.021_bib1","doi-asserted-by":"crossref","first-page":"466","DOI":"10.7326\/0003-4819-102-4-466","article-title":"Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia","volume":"102","author":"Michiels","year":"1985","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bcmd.2005.12.021_bib2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0190-9622(08)80005-9","article-title":"Erythromelalgia and thrombocythemia. A causal relation","volume":"22","author":"Michiels","year":"1990","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.bcmd.2005.12.021_bib3","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2559.1984.tb02379.x","article-title":"Histopathology of erythromelalgia in thrombocythemia","volume":"8","author":"Michiels","year":"1984","journal-title":"Histopathology"},{"key":"10.1016\/j.bcmd.2005.12.021_bib4","first-page":"343","article-title":"Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis","volume":"23","author":"Sch\u00f6r","year":"1997","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.bcmd.2005.12.021_bib5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1055\/s-0038-1653752","article-title":"Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin","volume":"73","author":"Van Genderen","year":"1995","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bcmd.2005.12.021_bib6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1155\/S0962935193000547","article-title":"Prostaglandin cyclooxygenase products but not thromboxane A2 are involved in the pathogenesis of erythromelalgia in thrombocythemia","volume":"2","author":"Michiels","year":"1993","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.bcmd.2005.12.021_bib7","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood.V80.8.1965.1965","article-title":"Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo","volume":"80","author":"Landolfi","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2005.12.021_bib8","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1055\/s-0038-1649916","article-title":"Increased thromboxane biosynthesis in essential thrombocythemia","volume":"74","author":"Rocca","year":"1995","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bcmd.2005.12.021_bib9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1365-2141.1999.01224.x","article-title":"Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low-dose aspirin as an antithrombotic agent","volume":"104","author":"Van Genderen","year":"1999","journal-title":"Brit. J. Haematol."},{"key":"10.1016\/j.bcmd.2005.12.021_bib10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1055\/s-0038-1650579","article-title":"Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation","volume":"76","author":"Van Genderen","year":"1996","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bcmd.2005.12.021_bib11","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.43.6.1107","article-title":"Transient neurologic and ocular manifestations in primary thombocythemia","volume":"43","author":"Michiels","year":"1993","journal-title":"Neurology"},{"issue":"Suppl. 1","key":"10.1016\/j.bcmd.2005.12.021_bib12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/10428199609074362","article-title":"Atypical transient ischemic attacks in thrombocythemia of various myeloproliferative disorders","volume":"22","author":"Michiels","year":"1996","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcmd.2005.12.021_bib13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0002-8703(91)91019-J","article-title":"Thrombocythemia and coronary artery disease","volume":"22","author":"Scheffer","year":"1991","journal-title":"Am. Heat J."},{"key":"10.1016\/j.bcmd.2005.12.021_bib14","first-page":"1622","article-title":"Die prophylaxe vascul\u00e4rer komplikationen bei polycythaemia vera und prim\u00e4rer thrombozyth\u00e4mie mit niedrigdosierter acetylsalicyls\u00e4ure","volume":"113","author":"Fr\u00f6hli","year":"1983","journal-title":"Schweiz. Med. Wochenschr."},{"key":"10.1016\/j.bcmd.2005.12.021_bib15","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1055\/s-2007-996111","article-title":"Aspirin in essential thrombocythemia: status quo and quo vadis","volume":"23","author":"Griesshammer","year":"1997","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.bcmd.2005.12.021_bib16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2141.1997.d01-2127.x","article-title":"Prevention and treatment of thrombotic complications in essential thrombocythemia: efficacy and safety of aspirin","volume":"97","author":"Van Genderen","year":"1997","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2005.12.021_bib17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera: results of the ECLAP trial","volume":"350","author":"Landolfi","year":"2004","journal-title":"N. Engl. J. Med."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979606000271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979606000271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:24:46Z","timestamp":1761049486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979606000271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S1079979606000271"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2005.12.021","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Platelet-mediated thrombotic complications in patients with ET: Reversal by aspirin, platelet reduction, and not by coumadin","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2005.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}